 HPN217 is being developed under a global license and option agreement with AbbVie Inc. ABBV and dosing of the first patient in a clinical trial has triggered a 50 million milestone payment to Harpoon. HPN217 is Harpoons third product candidate to enter the clinic and is based on Harpoons proprietary Tri-specific T cell Activating Construct TriTACTM platform designed to recruit a patients own immune cells to destroy tumors. 